{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T22:33:05Z","timestamp":1793658785964,"version":"4.5.1"},"reference-count":36,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2023,12,29]],"date-time":"2023-12-29T00:00:00Z","timestamp":1703808000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005972","name":"German Cancer Aid","doi-asserted-by":"publisher","award":["DETECT-CTC-HIGH\u201470114705"],"award-info":[{"award-number":["DETECT-CTC-HIGH\u201470114705"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Open Access Publication Fund of the University of T\u00fcbingen","award":["DETECT-CTC-HIGH\u201470114705"],"award-info":[{"award-number":["DETECT-CTC-HIGH\u201470114705"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>A frequent symptom of metastasized breast cancer (BC) includes the development of malignant pleural effusion (MPE), which contains malignant cells derived from the primary tumor site. The poor prognosis of MPE in metastasized BC indicates the necessity for dependable precision oncology and the importance of models representing the heterogenous nature of metastatic BC. In this study, we cultured MPE-derived metastatic tumor cells from four advanced BC patients using organoid technology. We assessed the expression of tumor-associated antigens on MPE-derived organoid lines by flow cytometry (FC). Based on an individual antigen expression pattern, patient-derived organoids were treated with adapter CAR-T cells (AdCAR-T) and biotinylated monoclonal antibodies targeting CD276, HER2, EGFR, TROP2, or EpCAM. Co-culture assays revealed specific organoid lysis by AdCAR-T depending on individual antigen expression patterns. Our results demonstrate that MPE-derived organoids can serve as a reliable tool for assessing the efficacy of AdCAR-T on metastatic BC in a patient-individualized manner. This approach could potentially be applied in a preclinical setting to instruct therapy decisions. Further, our study demonstrates the feasibility of precision immunotherapy utilizing AdCAR-T to target patient-individualized antigen patterns.<\/jats:p>","DOI":"10.3390\/cancers16010168","type":"journal-article","created":{"date-parts":[[2023,12,29]],"date-time":"2023-12-29T03:28:41Z","timestamp":1703820521000},"page":"168","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Precision Immunotherapy Utilizing Adapter CAR-T Cells (AdCAR-T) in Metastatic Breast Cancer Leads to Target Specific Lysis"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4969-5179","authenticated-orcid":false,"given":"Cansu E.","family":"\u00d6nder","sequence":"first","affiliation":[{"name":"Research Institute for Women\u2019s Health, University of T\u00fcbingen, 72076 T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moustafa","family":"Moustafa-Oglou","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology and Hematology, University Hospital T\u00fcbingen, 72076 T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4271-1498","authenticated-orcid":false,"given":"Sarah M.","family":"Schr\u00f6der","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Head and Neck Surgery, University of Ulm, 89081 Ulm, Germany"},{"name":"Department of Peptide-Based Immunotherapy, University and University Hospital T\u00fcbingen, 72076 T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1227-1118","authenticated-orcid":false,"given":"Andreas D.","family":"Hartkopf","sequence":"additional","affiliation":[{"name":"Department of Women\u2019s Health, University of T\u00fcbingen, 72076 T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3502-382X","authenticated-orcid":false,"given":"Andr\u00e9","family":"Koch","sequence":"additional","affiliation":[{"name":"Research Institute for Women\u2019s Health, University of T\u00fcbingen, 72076 T\u00fcbingen, Germany"},{"name":"Department of Women\u2019s Health, University of T\u00fcbingen, 72076 T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0520-7866","authenticated-orcid":false,"given":"Christian M.","family":"Seitz","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology and Hematology, University Hospital T\u00fcbingen, 72076 T\u00fcbingen, Germany"},{"name":"Cluster of Excellence iFIT (EXC 2180) \u201cImage-Guided and Functionally Instructed Tumor Therapies\u201d, University of T\u00fcbingen, 72076 T\u00fcbingen, Germany"},{"name":"German Cancer Consortium (DKTK), Partner Site T\u00fcbingen, a Partnership between German Cancer Research Center (DKFZ) and University Hospital T\u00fcbingen, 81675 Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,12,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"10869","DOI":"10.1073\/pnas.191367098","article-title":"Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications","volume":"98","author":"Sorlie","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s41572-019-0111-2","article-title":"Breast cancer","volume":"5","author":"Harbeck","year":"2019","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/s43018-021-00229-1","article-title":"Understanding and overcoming tumor heterogeneity in metastatic breast cancer treatment","volume":"2","author":"Pasha","year":"2021","journal-title":"Nat. Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ejca.2013.10.004","article-title":"A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases","volume":"50","author":"Aurilio","year":"2014","journal-title":"Eur. J. Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1093\/annonc\/mdq751","article-title":"Should liver metastases of breast cancer be biopsied to improve treatment choice?","volume":"22","author":"Curigliano","year":"2011","journal-title":"Ann. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s10549-020-05746-8","article-title":"Estrogen, progesterone, and human epidermal growth factor receptor 2 discordance between primary and metastatic breast cancer","volume":"183","author":"Walter","year":"2020","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_8","first-page":"CD010529","article-title":"Interventions for the management of malignant pleural effusions: A network meta-analysis","volume":"4","author":"Dipper","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/0360-3016(77)90195-X","article-title":"Pathogenesis of pleural effusion in carcinoma of the breast","volume":"2","author":"Weichselbaum","year":"1977","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"ii32","DOI":"10.1136\/thx.2010.136994","article-title":"Management of a malignant pleural effusion: British Thoracic Society Pleural Disease Guideline 2010","volume":"65","author":"Roberts","year":"2010","journal-title":"Thorax"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Sorolla, M.A., Sorolla, A., Parisi, E., Salud, A., and Porcel, J.M. (2021). Diving into the Pleural Fluid: Liquid Biopsy for Metastatic Malignant Pleural Effusions. Cancers, 13.","DOI":"10.3390\/cancers13112798"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/nrc2193","article-title":"Modelling breast cancer: One size does not fit all","volume":"7","author":"Rosen","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.cell.2017.11.010","article-title":"A Living Biobank of Breast Cancer Organoids Captures Disease Heterogeneity","volume":"172","author":"Sachs","year":"2018","journal-title":"Cell"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Onder, C.E., Ziegler, T.J., Becker, R., Brucker, S.Y., Hartkopf, A.D., Engler, T., and Koch, A. (2023). Advancing Cancer Therapy Predictions with Patient-Derived Organoid Models of Metastatic Breast Cancer. Cancers, 15.","DOI":"10.3390\/cancers15143602"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/s41568-018-0007-6","article-title":"Organoids in cancer research","volume":"18","author":"Drost","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"ref_16","first-page":"171","article-title":"Breast Cancer Treatment","volume":"104","author":"Trayes","year":"2021","journal-title":"Am. Fam. Physician"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/978-981-10-6020-5_17","article-title":"New Approaches in CAR-T Cell Immunotherapy for Breast Cancer","volume":"1026","author":"Wang","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: Current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.7150\/ijbs.70120","article-title":"CAR-T Cell Therapy for Breast Cancer: From Basic Research to Clinical Application","volume":"18","author":"Yang","year":"2022","journal-title":"Int. J. Biol. Sci."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1158\/2159-8290.CD-17-1084","article-title":"CNS Endothelial Cell Activation Emerges as a Driver of CAR T Cell-Associated Neurotoxicity","volume":"7","author":"Mackall","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1182\/blood-2015-08-665547","article-title":"Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy","volume":"127","author":"Gardner","year":"2016","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e215","DOI":"10.3324\/haematol.2017.183459","article-title":"Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma","volume":"103","author":"Shalabi","year":"2018","journal-title":"Haematologica"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2003532","DOI":"10.1080\/2162402X.2021.2003532","article-title":"Novel adapter CAR-T cell technology for precisely controllable multiplex cancer targeting","volume":"10","author":"Seitz","year":"2021","journal-title":"Oncoimmunology"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Atar, D., Mast, A.S., Scheuermann, S., Ruoff, L., Seitz, C.M., and Schlegel, P. (2022). Adapter CAR T Cell Therapy for the Treatment of B-Lineage Lymphomas. Biomedicines, 10.","DOI":"10.3390\/biomedicines10102420"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Carter, M.E., Hartkopf, A.D., Wagner, A., Volmer, L.L., Brucker, S.Y., Berchtold, S., Lauer, U.M., and Koch, A. (2022). A Three-Dimensional Organoid Model of Primary Breast Cancer to Investigate the Effects of Oncolytic Virotherapy. Front. Mol. Biosci., 9.","DOI":"10.3389\/fmolb.2022.826302"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1097\/SLA.0b013e3181f1939d","article-title":"B7-h3 ligand expression by primary breast cancer and associated with regional nodal metastasis","volume":"252","author":"Arigami","year":"2010","journal-title":"Ann. Surg."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"654684","DOI":"10.3389\/fonc.2021.654684","article-title":"The Role of CD276 in Cancers","volume":"11","author":"Liu","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/mt.2010.24","article-title":"Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2","volume":"18","author":"Morgan","year":"2010","journal-title":"Mol. Ther."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Schepisi, G., Gianni, C., Palleschi, M., Bleve, S., Casadei, C., Lolli, C., Ridolfi, L., Martinelli, G., and De Giorgi, U. (2023). The New Frontier of Immunotherapy: Chimeric Antigen Receptor T (CAR-T) Cell and Macrophage (CAR-M) Therapy against Breast Cancer. Cancers, 15.","DOI":"10.3390\/cancers15051597"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"4669","DOI":"10.1182\/blood-2005-09-3775","article-title":"Antibody-dependent cellular cytotoxicity (ADCC) is mediated by genetically modified antigen-specific human T lymphocytes","volume":"107","author":"Clemenceau","year":"2006","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1158\/0008-5472.CAN-13-1365","article-title":"T lymphocytes expressing a CD16 signaling receptor exert antibody-dependent cancer cell killing","volume":"74","author":"Kudo","year":"2014","journal-title":"Cancer Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"6436","DOI":"10.1158\/1078-0432.CCR-12-1449","article-title":"Redirecting gene-modified T cells toward various cancer types using tagged antibodies","volume":"18","author":"Tamada","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"E459","DOI":"10.1073\/pnas.1524155113","article-title":"Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies","volume":"113","author":"Rodgers","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e458","DOI":"10.1038\/bcj.2016.61","article-title":"Switching CAR T cells on and off: A novel modular platform for retargeting of T cells to AML blasts","volume":"6","author":"Cartellieri","year":"2016","journal-title":"Blood Cancer J."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/j.cell.2018.03.038","article-title":"Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses","volume":"173","author":"Cho","year":"2018","journal-title":"Cell"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1182\/blood.2020009759","article-title":"Proof of concept for a rapidly switchable universal CAR-T platform with UniCAR-T-CD123 in relapsed\/refractory AML","volume":"137","author":"Wermke","year":"2021","journal-title":"Blood"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/1\/168\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:43:52Z","timestamp":1760132632000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/1\/168"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,29]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1]]}},"alternative-id":["cancers16010168"],"URL":"https:\/\/doi.org\/10.3390\/cancers16010168","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,29]]}}}